Logo image of BMGL

BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

USA - NASDAQ:BMGL - VGG0864B1031 - Common Stock

1.61 USD
-0.03 (-1.83%)
Last: 10/3/2025, 8:25:51 PM
1.64 USD
+0.03 (+1.86%)
After Hours: 10/3/2025, 8:25:51 PM
Fundamental Rating

3

Taking everything into account, BMGL scores 3 out of 10 in our fundamental rating. BMGL was compared to 101 industry peers in the Health Care Providers & Services industry. BMGL has only an average score on both its financial health and profitability. BMGL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

BMGL had positive earnings in the past year.
In the past year BMGL has reported a negative cash flow from operations.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 1M 2M 3M 4M

1.2 Ratios

The Return On Assets of BMGL (11.76%) is better than 97.03% of its industry peers.
BMGL has a better Return On Equity (24.18%) than 90.10% of its industry peers.
BMGL has a better Return On Invested Capital (36.92%) than 100.00% of its industry peers.
BMGL had an Average Return On Invested Capital over the past 3 years of 29.84%. This is significantly above the industry average of 9.20%.
The last Return On Invested Capital (36.92%) for BMGL is above the 3 year average (29.84%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 11.76%
ROE 24.18%
ROIC 36.92%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 10 20 30 40 50

1.3 Margins

BMGL has a better Profit Margin (11.64%) than 98.02% of its industry peers.
BMGL has a Operating Margin of 32.46%. This is amongst the best in the industry. BMGL outperforms 98.02% of its industry peers.
Industry RankSector Rank
OM 32.46%
PM (TTM) 11.64%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

BMGL has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for BMGL remains at a similar level compared to 1 year ago.
The debt/assets ratio for BMGL has been reduced compared to a year ago.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

An Altman-Z score of 4.08 indicates that BMGL is not in any danger for bankruptcy at the moment.
BMGL has a better Altman-Z score (4.08) than 73.27% of its industry peers.
A Debt/Equity ratio of 0.55 indicates that BMGL is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.55, BMGL perfoms like the industry average, outperforming 59.41% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Altman-Z 4.08
ROIC/WACC4.25
WACC8.68%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2M 4M 6M

2.3 Liquidity

BMGL has a Current Ratio of 1.88. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
BMGL's Current ratio of 1.88 is fine compared to the rest of the industry. BMGL outperforms 70.30% of its industry peers.
BMGL has a Quick Ratio of 1.87. This is a normal value and indicates that BMGL is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of BMGL (1.87) is better than 73.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.88
Quick Ratio 1.87
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for BMGL have decreased strongly by -43.56% in the last year.
Looking at the last year, BMGL shows a small growth in Revenue. The Revenue has grown by 1.99% in the last year.
EPS 1Y (TTM)-43.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.92%
Revenue 1Y (TTM)1.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 23.00, which indicates a rather expensive current valuation of BMGL.
Based on the Price/Earnings ratio, BMGL is valued a bit cheaper than the industry average as 64.36% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of BMGL to the average of the S&P500 Index (27.86), we can say BMGL is valued inline with the index average.
Industry RankSector Rank
PE 23
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BMGL is valued cheaper than 95.05% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 4.56
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

BMGL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (10/3/2025, 8:25:51 PM)

After market: 1.64 +0.03 (+1.86%)

1.61

-0.03 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.7%
Inst Owner ChangeN/A
Ins Owners13.65%
Ins Owner ChangeN/A
Market Cap30.25M
AnalystsN/A
Price TargetN/A
Short Float %5.96%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 23
Fwd PE N/A
P/S 2.59
P/FCF N/A
P/OCF N/A
P/B 5.37
P/tB 5.37
EV/EBITDA 4.56
EPS(TTM)0.07
EY4.35%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.62
BVpS0.3
TBVpS0.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 11.76%
ROE 24.18%
ROCE 67.42%
ROIC 36.92%
ROICexc 1026.25%
ROICexgc 1026.25%
OM 32.46%
PM (TTM) 11.64%
GM N/A
FCFM N/A
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
ROICexc(3y)34.59%
ROICexc(5y)N/A
ROICexgc(3y)34.59%
ROICexgc(5y)N/A
ROCE(3y)47.14%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF N/A
Debt/EBITDA 0.73
Cap/Depr 2.99%
Cap/Sales 0.12%
Interest Coverage 27.55
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.88
Quick Ratio 1.87
Altman-Z 4.08
F-Score3
WACC8.68%
ROIC/WACC4.25
Cap/Depr(3y)5.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.32%
Cap/Sales(5y)N/A
Profit Quality(3y)134.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.99%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3YN/A
OCF growth 5YN/A